AbbVie Inc news

   Watch this stock
Showing stories 1 - 10 of about 158   

Articles published

ABBV 93.61 -0.84 (-0.89%)
price chart
AbbVie Inc. (NYSE:ABBV) Short Interest Down 21.2% in October
AbbVie logo AbbVie Inc. (NYSE:ABBV) was the target of a large decline in short interest in October. As of October 13th, there was short interest totalling 14,213,032 shares, a decline of 21.2% from the September 29th total of 18,045,411 shares.
Pinnacle Financial Partners Inc. Acquires 33375 Shares of AbbVie Inc. (NYSE ...  Dispatch Tribunal
AbbVie Inc. (ABBV) Shares Bought by Penobscot Investment Management Company Inc.  StockNewsTimes
AbbVie: Another Spectacular Quarter From This Dividend Aristocrat
The company's performance in the quarter was fantastic. Revenues increased by ~9% while adjusted diluted earnings-per-share expanded by ~17%.
AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise  PharmaLive (press release)
Physicians Financial Services, Inc. Buys DowDuPont Inc, Red Hat Inc, AbbVie ...
Physicians Financial Services, Inc. initiated holdings in AbbVie Inc. The purchase prices were between $69.85 and $89.22, with an estimated average price of $76.06.
AbbVie Promises Too Much, Risks Delivering Too Little: Gadfly
AbbVie Inc. has gotten some wins lately. But it may be guilty of over-celebrating. The company provided boosted long-term sales forecasts last week, commemorating strong third-quarter sales of its lead drug Humira and a deal with Amgen Inc. that will ...
AbbVie inks $225M neurodegenerative drug development deal with Alector
Under the terms of the agreement, AbbVie will pay $205M upfront and a future equity investment up to $20M for the option to globally develop and commercialize two drug targets.
With new approach to Alzheimer's, Peninsula company seals $225M deal ...  San Francisco Business Times
Alzheimer's immunotherapy boosted by AbbVie deal  Financial Times
Will This Only Make Things Worse? – AbbVie Inc. (ABBV), American Eagle ...
For AbbVie Inc. (NYSE:ABBV) Thursday was another day of strong-handed buying, with the low volume day punctuated by a rise from previous close.
AbbVie Inc. (ABBV) Expected to Post Quarterly Sales of $7.56 Billion
AbbVie logo Wall Street brokerages expect AbbVie Inc. (NYSE:ABBV) to announce $7.56 billion in sales for the current quarter, according to Zacks.
AbbVie Inc. (NYSE:ABBV) Earns Buy Rating from SunTrust Banks, Inc.
AbbVie logo AbbVie Inc. (NYSE:ABBV)'s stock had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc. in a research note issued on Monday, October 30th, The Fly reports.
AbbVie Inc. (ABBV) Insider Henry O. Gosebruch Sells 18300 Shares  StockNewsTimes
Why AbbVie Inc. (ABBV) Is Being Added to Investors Watchlist?  StockNewsGazette
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
This quarter, AbbVie expects Humira sales to rise in the high-teens range while internationally, sales are estimated to increase in a mid-single-digit range on an operational basis.
AbbVie Inc (ABBV) Earnings: 12 Things to Know
Wall Street was looking for ABBV to report earnings per share of $1.38 on revenue of $7.00 billion for the quarter. Operating income for the quarter was $2.71 billion, which is up from the $2.36 billion reported in the third quarter of 2016.
Checking the Overall Picture for AbbVie Inc. (ABBV)  StockNewsJournal